GeekWire
  • Home
  • News
    • Amazon
    • Civic presented by Microsoft
    • Geek Life presented by Network of Giving
    • Health/Life Sciences
    • Microsoft
    • Podcasts
    • Space
    • Startups
    • Sustainability
    • Tech Moves
    • Bot or Not
    • GeekWire on the Road: Spokane
    • Microsoft at 50 presented by Accenture
    • Tech Vets presented by Northern Trust
  • Jobs
  • Events
    • Community Calendar
    • GeekWire Events
  • Lists
    • Amazon Office Buildings
    • GeekWire 200 presented by JPMorganChase
    • GeekWire Startup List
    • GeekWire Startup Resources
    • GeekWire Startup Spaces
    • Layoff Tracker
    • M&As and IPOs
    • Northwest Women VC & Angel Investor List
    • Recent Fundings
    • Seattle Engineering Outposts
    • Venture Capital Directory
  • Members
    • Health Benefits
    • Memberships
  • Studios
    • GeekWire Studios: Let Us Tell Your Story
    • Nebius at NVIDIA GTC 2025 sponsored by Nebius
    • AWS Marketplace Seller Conference 2024 sponsored by AWS
    • AWS Summit: New York Partner Spotlights sponsored by AWS
    • Does Compute presented by Carnegie Mellon University
    • Guide to re:Invent sponsored by AWS
    • Innovate State
    • Money Hacks presented by BECU
    • Tech Connect at Dreamforce 2024 sponsored by RSM US LLP
    • Uncommon Thinkers Welcome sponsored by Greater Seattle Partners
    • Zuper at Inbound sponsored by Zuper
  • About
    • About GeekWire
    • Advertise
    • Contact Us
    • Email Newsletters
    • Reprints & Permissions
    • Sponsors

Kestra Medical Technologies

Kestra Medical Technologies, maker of wearable cardiac devices, files for IPO

Kestra Medical Technologies, a Kirkland, Wash.-based company selling cardiac monitoring and therapeutic devices, filed for an initial public offering on Monday. The company’s revenue more than tripled from $7.6 million… Read More

Life sciences news: COVID-19 shot clinical data, Bill Gates on preventing the next pandemic

The week in life sciences in the Pacific Northwest started with disappointing data for Eliem Therapeutics. Its lead compound failed to show benefit in a clinical trial for diabetic neuropathic… Read More

A Word From Our Sponsors

About

  • About GeekWire
  • Contact Us
  • Ask About Advertising
  • Send Us a Tip
  • Become a GeekWire Member
  • Join Our Startup List
  • Reprints and Permissions

Follow

GeekWire Newsletters

Catch every headline in your inbox

Read GeekWire

  • Apple News
  • Google News

Legal

  • Privacy Policy
  • Terms of Use
  • Sponsored Content Policy
Return to Top of Page
© 2011-2025 GeekWire, LLC
Do Not Sell or Share My Personal information
Limit the Use Of My Sensitive Personal Information
Consent Preferences